Pacira BioSciences Under Pressure for Strategic Changes Amid Shareholder Discontent

Pacira BioSciences Faces Pressure for Strategic Overhaul Amid Shareholder Discontent

Pacira BioSciences, Inc. finds itself in a critical situation as DOMA Perpetual Capital Management LLC, a significant shareholder with a 6.8% stake, calls for a full sale of the company. In a letter dated November 10, 2025, DOMA expresses deep concerns about the company's financial mismanagement and strategic direction. The letter outlines specific grievances, including excessive spending on initiatives perceived as detrimental to shareholder value, such as the relocation of the company's headquarters. DOMA argues that these decisions have resulted in unnecessary cash burn, further exacerbating the company's financial challenges.

The shareholder's dissatisfaction extends beyond operational expenditures. DOMA highlights the troubling trajectory of Pacira's product sales, particularly noting a 2% decrease in sales for its lead product, Zilretta, in the third quarter. This decline raises alarms about the company’s ability to maintain revenue growth amidst intense competition in the biopharmaceutical market. Additionally, the letter critiques the compensation structure for executives, which could amount to approximately 6% of the company’s market capitalization in 2025, overshadowing the company's operating income and raising questions about the alignment of management incentives with shareholder interests.

With a clear call for the Board of Directors to engage investment bankers and pursue a sale process, DOMA emphasizes the urgency for Pacira to implement decisive changes. The shareholder advocates for a shift in leadership and strategy to restore investor confidence and enhance shareholder value. Their willingness to increase their investment contingent upon these changes underscores the potential for further shareholder activism if the Board does not address the outlined issues promptly.

In related developments, the ongoing scrutiny from significant shareholders like DOMA may compel Pacira's Board to reconsider its strategic approach. The biopharmaceutical industry is characterized by rapid innovation and evolving market dynamics, making effective leadership and sound financial management crucial for success. As Pacira navigates this challenging landscape, maintaining open lines of communication with its shareholders will be essential in rebuilding trust and ensuring long-term viability.

The pressure from DOMA reflects broader concerns in the industry about executive compensation and strategic decision-making. As shareholders increasingly demand accountability, companies like Pacira must balance the need for innovation with prudent financial practices to secure their future in a competitive market.